Advances in diabetes for the millennium

Drug therapy of type 2 diabetes CME

Marc Rendell

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.

Original languageEnglish
JournalMedGenMed Medscape General Medicine
Volume6
Issue number3 SUPPL.
StatePublished - 2004

Fingerprint

Type 2 Diabetes Mellitus
Glucagon-Like Peptides
Disaccharidases
Glucose
Drug Therapy
Thiazolidinediones
Metformin
Weight Gain
Meals
Insulin Resistance
Blood Glucose
Insulin
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Advances in diabetes for the millennium : Drug therapy of type 2 diabetes CME. / Rendell, Marc.

In: MedGenMed Medscape General Medicine, Vol. 6, No. 3 SUPPL., 2004.

Research output: Contribution to journalArticle

@article{86e1c25fdd194b939756d57dd6a21607,
title = "Advances in diabetes for the millennium: Drug therapy of type 2 diabetes CME",
abstract = "There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.",
author = "Marc Rendell",
year = "2004",
language = "English",
volume = "6",
journal = "MedGenMed Medscape General Medicine",
issn = "1531-0132",
publisher = "Medscape Health Network",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Advances in diabetes for the millennium

T2 - Drug therapy of type 2 diabetes CME

AU - Rendell, Marc

PY - 2004

Y1 - 2004

N2 - There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.

AB - There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.

UR - http://www.scopus.com/inward/record.url?scp=27444433718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27444433718&partnerID=8YFLogxK

M3 - Article

VL - 6

JO - MedGenMed Medscape General Medicine

JF - MedGenMed Medscape General Medicine

SN - 1531-0132

IS - 3 SUPPL.

ER -